Committee considers allowing board‑certified psychiatric pharmacists to participate in involuntary treatment proceedings

House Bill 2453 drew competing expert testimony on Jan. 27 as committee members weighed whether to add board‑certified psychiatric pharmacists (BCPPs) to the list of professionals authorized to sign certain petitions and provide concurring medical opinions in involuntary treatment proceedings.

Staff summarized changes: adding BCPPs to the professionals who may sign 14‑day inpatient commitment petitions and to those who may provide concurring medical opinions for involuntary medication under Less Restrictive Alternative (LRA) orders. Committee witnesses described the BCPP credential as a rigorous specialty certification (pharmacy doctorate plus residency or several years of clinical psychiatric practice and a specialty exam) and said roughly 47 BCPPs exist in Washington.

Supporters — including practicing BCPPs, psychiatric physician assistants and behavioral health nonprofits — argued the change is a workforce fix that would improve continuity of care because BCPPs already manage complex psychotropic regimens under collaborative drug therapy agreements and participate directly in patient treatment. "Excluding board‑certified psychiatric pharmacists from these events means missing an opportunity to expand access," one testifier said, and another said allowing BCPPs to testify avoids inefficient handoffs to other clinicians and improves courtroom testimony about medication management.

Medical doctors and the Washington State Psychiatric Association raised concerns that BCPPs do not have training and statutory authority to make formal psychiatric diagnoses and to assess risk factors such as violence and grave disability — matters that often undergird involuntary commitment. The Citizens Commission on Human Rights and other civil‑liberties voices urged a "no" vote, arguing the change would expand the pool of signatories and could weaken civil‑liberty protections given existing disparities in the mental‑health system.

Testimony from psychiatrists and clinical organizations stressed that BCPPs who would participate typically work under collaborative agreements and already manage medications for diagnosed patients; supporters said BCPP participation would be limited to providing expert testimony about medication response and safety rather than supplanting diagnostic authority.

Committee members asked about the practical effect on involuntary commitments and whether expanding the pool of eligible professionals might increase the number of commitments; proponents said the standard for commitment requires documentation and judicial oversight and that the change would primarily support continuity and clinical detail in hearings. No committee vote was recorded on Jan. 27.